NCT05959109View on ClinicalTrials.gov

A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

57

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

January 11, 2024

Study Completion Date

January 11, 2024

Conditions

Healthy

Interventions

DRUG

Peresolimab

Administered SC

Trial Locations (1)

75247

LabCorp CRU, Inc., Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY